High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

This study is currently recruiting participants.

Verified by Alberta Cancer Board, April 2007

First Received: August 3, 2005 Last Updated: September 22, 2008 History of Changes

Sponsor:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00126854

Purpose

The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for prostate cancer. Three Tesla MRSI may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.

Condition	Intervention
Prostatic Neoplasm	Procedure: Magnetic Resonance Spectroscopy Imaging

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

pilot study meant to establish scanning parameters on 3T MRSI

Secondary Outcome Measures:

safety/toxicity

Estimated Enrollment:	10
Study Start Date:	October 2005
Estimated Study Completion Date:	November 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Suitable candidate for prostate brachytherapy to treat prostate cancer
Patient signs a study consent form

Exclusion Criteria:

Have received other radiotherapy for prostate cancer or hormone treatments
Has contraindication to MRSI scanning
Does not sign study consent form

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126854

Contacts

Contact: Don Yee, MD

780-432-8749

donyee@cancerboard.ab.ca

Locations

Canada, Alberta
Cross Cancer Institute	Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca
Principal Investigator: Don Yee, MD

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Don Yee, MD

Alberta Cancer Board

More Information

No publications provided

Study ID Numbers:	NA-15-0003
Study First Received:	August 3, 2005
Last Updated:	September 22, 2008
ClinicalTrials.gov Identifier:	NCT00126854 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

brachytherapy
magnetic resonance spectroscopy

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 22, 2009